ArticleOncoTargets and therapy2017

Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status.

Nobuhiro Hata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.